Cytek Biosciences, Inc.
Financials
Valuation Metrics
Cytek Biosciences, Inc.'s Market Cap is $684M. At end of 2025 it was $647M. Ranked #2669 of 3,121 in US market (top 86%), #1142 of 1,463 on NASDAQ (top 78%), #164 of 205 in Health Care Equipment & Services (top 80%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $684M | US#2,669/3,121 Sec#164/205 |
| Revenue | $207M | US#2,569/3,121 Sec#170/205 |
| Net Income | $-81M | US—/3,121 Sec—/205 |
| Total Assets | $447M | US#2,815/3,121 Sec#163/205 |
| Net Assets | $322M | US#2,492/3,121 Sec#142/205 |
| Employees | 702 | US#2,133/3,121 Sec#151/205 |
| Value | ||
| P/B | 2.13x | US#1,309/3,121 Sec#63/205 |
| P/S | 3.31x | US#1,814/3,121 Sec#125/205 |
| FCF Yield | -1.76% | US—/3,121 Sec—/205 |
| Profitability | ||
| ROE | -25.03% | US#2,529/3,121 Sec#153/205 |
| ROA | -18.03% | US#2,777/3,121 Sec#172/205 |
| Op. Margin | -21.60% | US#2,611/3,121 Sec#166/205 |
| Revenue Growth | 5.44% | US#1,761/3,121 Sec#126/205 |
| Financial Health | ||
| Debt Ratio | 38.82% | US#441/3,121 Sec#47/205 |
| Total Debt | $26M | US#2,716/3,121 Sec#167/205 |
| FCF | $-12M | US#2,386/3,121 Sec#155/205 |
| Cash | $74M | US#2,396/3,121 Sec#147/205 |
| Current Ratio | 4.48x | US#533/3,121 Sec#48/205 |
| Dividend | ||
| Div. Yield | 0.00% | US—/3,121 Sec—/205 |
| Payout Ratio | 0.00% | US—/3,121 Sec—/205 |
| Performance | ||
| 1Y Return | 29.58% | US#849/3,121 Sec#69/205 |
| 1M Return | 12.77% | US#206/3,121 Sec#30/205 |
| From 52W High | -14.24% | US#1,187/3,121 Sec#86/205 |
| 1Y MDD | -42.86% | US#2,153/3,121 Sec#128/205 |
| Trading | ||
| Volume | 1,751,423 shares | US#763/3,121 Sec#41/205 |
| Trading Value | $9M | US#2,265/3,121 Sec#151/205 |
| Per Share | ||
| EPS | $-0.62 | US—/3,121 Sec—/205 |
| BPS | $2.49 | US#2,541/3,121 Sec#166/205 |
Company Info
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.